Estrogen Receptor Beta (ERβ): A Ligand Activated Tumor Suppressor
Rahul Mal(The Ohio State University), Mathew Cherian(The Ohio State University Wexner Medical Center), Joel David(The Ohio State University), Jasmine M. Manouchehri(The Ohio State University Wexner Medical Center), Robert Wesolowski(The Ohio State University Wexner Medical Center), Jharna Datta(The Ohio State University), Daniel G. Stover(Harvard University), Jeffrey VanDeusen(The Ohio State University), Bhuvaneswari Ramaswamy(The Ohio State University), Ramesh K. Ganju(The Ohio State University), Maryam B. Lustberg(Yale Cancer Center), Mahmoud Kassem(The Ohio State University), Meghna Vallabhaneni(The Ohio State University), Nicole Williams(The Ohio State University), Alexa Magner(The Ohio State University), Sagar Sardesai(The Ohio State University), Natalie Willingham(The Ohio State University)
Cited by 127
Related Papers
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
|Nature|2016|629
The α-Chemokine, Stromal Cell-derived Factor-1α, Binds to the Transmembrane G-protein-coupled CXCR-4 Receptor and Activates Multiple Signal Transduction Pathways
|Journal of Biological Chemistry|1998|618
Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells
|Proceedings of the National Academy of Sciences|2017|373